Cardio-protective effect of dapagliflozin against doxorubicin induced cardiomyopathy in rats

• Published in: European review for medical and pharmacological sciences Vol. 26; no. 12; p. 4403
• Main Authors: Belen, E, Canbolat, I P, Yigittürk, G, Cetinarslan, Ö, Akdeniz, C S, Karaca, M, Sönmez, M, Erbas, O
• Format: Journal Article
• Language: English
• Published: Italy 01.06.2022
• Subjects: Animals; Benzhydryl Compounds; Cardiomyopathies - chemically induced; Cardiomyopathies - prevention & control; Diabetes Mellitus, Type 2 - chemically induced; Doxorubicin - adverse effects; Glucosides; Rats; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Tumor Necrosis Factor-alpha

Cancer is the second most common non-communicable disease group in the world and its frequency is increasing. In parallel, side effects of drugs used in cancer treatment are frequently encountered. Doxorubicin (DOX) is one of the most effective multi-purpose anticancer drugs. However, its use is sig...